drugset
drugset / Trial / NCT04481594

A Study to Evaluate the Safety and Tolerability of Single and Multiple Ascending Doses of HPN-01 in Healthy Subjects

NCT04481594 ↗

Phase 1 Unknown 72 enrolled Hepanova Inc.
RandomizedSequentialDouble-blindTreatment

Summary

This study is a randomized, double-blind, placebo-controlled first-in-human study in which the safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered HPN-01 will be evaluated in healthy subjects

Timeline

Start
2020-09-08
Primary completion
2021-07
Completion
2021-07

Drugs

EvaluationDrugModalityDoseRoute
Subject HPN-01 Unknown 25 mg Oral
Subject HPN-01 Unknown 50 mg Oral
Subject HPN-01 Unknown 100 mg Oral
Subject HPN-01 Unknown 150 mg Oral
Subject HPN-01 Unknown 200 mg Oral
Subject HPN-01 Unknown 300 mg Oral

Indications

metabolic dysfunction-associated steatohepatitis